» Articles » PMID: 26781471

Long-term Visual Outcomes in Intraocular Retinoblastoma with Eye Preservation

Overview
Specialty Oncology
Date 2016 Jan 20
PMID 26781471
Citations 8
Authors
Affiliations
Soon will be listed here.
Abstract

Purpose: Inconsistent data exist on long-term visual outcomes in survivors of retinoblastoma. No studies have been reported on role of ocular coherence tomography (OCT) in predicting visual acuity. We assessed visual acuity in patients with retinoblastoma treated at our center in whom affected eyes were preserved.

Methods: Patients who had completed a 2-year follow-up and were more than 5 years of age at assessment were included. Clinical data were obtained from database and factors predicting visual acuity were analyzed. OCT was performed in these patients to assess central macular thickness (CMT).

Results: Visual outcomes were assessed in 45 eyes of 43 patients, of which 38 (88 %) had bilateral retinoblastoma. The median age at diagnosis was 12 months. Sixty percent (27/45) had International classification of retinoblastoma group C or D disease with 40 % eyes showing macular lesions. The far visual acuity was better than 6/12 in 53 % (24/45), 6/12 to 6/60 in 40 % (18/45) and 6/60 in 7 % (6/60). Macular location and International classification of retinoblastoma predicted poor vision (p = 0.06 and 0.07, respectively). CMT was less than 200 μm in 3 of 36 eyes (8 %) and 1 eye showed epiretinal membrane. Radiotherapy was associated with foveal thinning (p = 0.003). Two of 3 eyes with foveal thinning had a vision of 6/60.

Conclusions: Good visual outcomes were observed in half of retinoblastoma patients treated with eye preservation. Macular location and International classification of retinoblastoma group C and D predicted poor visual acuity, while previous radiotherapy predicted foveal thinning, which was associated with poor visual acuity.

Citing Articles

Bilateral familial retinoblastoma diagnosed via optical coherence tomography following a normal funduscopic exam.

Allphin M, Ramasubramanian A Fam Cancer. 2024; 24(1):12.

PMID: 39680226 DOI: 10.1007/s10689-024-00424-w.


Strabismus management in retinoblastoma survivors.

Masoomian B, Shields C, Esfahani H, Khalili A, Ghassemi F, Rishi P BMC Ophthalmol. 2024; 24(1):114.

PMID: 38481156 PMC: 10935820. DOI: 10.1186/s12886-024-03379-9.


Retinoblastoma treatment in a Brazilian population. Presentation and long-term results.

Bonanomi M, de Almeida M, Hollaender M, Bonanomi R, Monteiro M Cancer Med. 2024; 13(3):e6683.

PMID: 38243643 PMC: 10905530. DOI: 10.1002/cam4.6683.


Retinoblastoma and vision.

Warda O, Naeem Z, Roelofs K, Sagoo M, Reddy M Eye (Lond). 2022; 37(5):797-808.

PMID: 34987197 PMC: 10050411. DOI: 10.1038/s41433-021-01845-y.


Treatment Outcomes of Focal Laser Consolidation during Chemoreduction for Group B Retinoblastoma.

Kim J, Aziz H, McGovern K, Zolfaghari E, Jubran R, Murphree A Ophthalmol Retina. 2019; 1(5):361-368.

PMID: 31047562 PMC: 7448755. DOI: 10.1016/j.oret.2017.01.014.


References
1.
Shields C, Shields J . Basic understanding of current classification and management of retinoblastoma. Curr Opin Ophthalmol. 2006; 17(3):228-34. DOI: 10.1097/01.icu.0000193079.55240.18. View

2.
Schefler A, Abramson D . Retinoblastoma: what is new in 2007-2008. Curr Opin Ophthalmol. 2008; 19(6):526-34. DOI: 10.1097/ICU.0b013e328312975b. View

3.
Houston S, Murray T, Wolfe S, Fernandes C . Current update on retinoblastoma. Int Ophthalmol Clin. 2010; 51(1):77-91. PMC: 3079394. DOI: 10.1097/IIO.0b013e3182010f29. View

4.
Weiss A, Karr D, KALINA R, Lindsley K, Pendergrass T . Visual outcomes of macular retinoblastoma after external beam radiation therapy. Ophthalmology. 1994; 101(7):1244-9. DOI: 10.1016/s0161-6420(94)31182-1. View

5.
Desjardins L, Chefchaouni M, Lumbroso L, Levy C, Asselain B, Bours D . Functional results after treatment of retinoblastoma. J AAPOS. 2002; 6(2):108-11. DOI: 10.1067/mpa.2002.121451. View